SCHEMBL6874416

SCHEMBL6874416

CC(C)(C)OC(=O)N1CCC(Oc2ccc(C(=O)NCCOc3cc(C#N)ccc3OCc3ccccc3)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.52
F10 P00742 3/20 0.47
F2 P00734 1/20 0.45
YAP1 P46937 3/20 0.44
KDM4E B2RXH2 1/20 0.44
PKM P14618 1/20 0.44
ALK Q9UM73 1/20 0.42
CHRM4 P08173 1/20 0.42
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
OPRM1 P35372 2/20 0.41
OPRD1 P41143 2/20 0.41
KIT P10721 1/20 0.41
FLT3 P36888 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KMT2A Q03164 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3897950 0.87 GPR119 (0.56) GPR119F10F2KDM4EPKM
SCHEMBL3912286 0.84 F10 (0.60) GPR119F10F2KDM4EPKM
SCHEMBL6873900 0.82 GPR119 (0.51) GPR119F10F2ALK
SCHEMBL6873899 0.82 GPR119 (0.51) GPR119F10F2ALK
SCHEMBL6555091 0.81 GPR119 (0.50) GPR119F10F2ALK
SCHEMBL6864795 0.81 GPR119 (0.51) GPR119F10F2ALKPDE4A
SCHEMBL6864800 0.81 GPR119 (0.51) GPR119F10F2ALKPDE4A
SCHEMBL3899270 0.80 GPR119 (0.48) GPR119F10F2ALKPDE4A
SCHEMBL3899273 0.80 GPR119 (0.48) GPR119F10F2ALKPDE4A
SCHEMBL8120896 0.79 GPR119 (0.52) GPR119YAP1ALKALDH1A1PRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812231-B2 INHIBITING ACTIVATED BLOOD-COAGULATION FACTOR X AJINOMOTO CO., INC. (JP) 2004-11-02 US disclosed
US-20020107290-A1 Benzamidine derivative AJINOMOTO CO., INC. (JP) 2002-08-08 US disclosed
US-6410538-B2 ANTICOAGULANT OR AN AGENT FOR TREATING OR PREVENTING THROMBI OR EMBOLI AJINOMOTO CO., INC. (JP) 2002-06-25 US disclosed
US-20010056123-A1 Anticoagulant or an agent for treating or preventing thrombi or emboli AJINOMOTO CO., INC (JP) 2001-12-27 US disclosed
EP-1086946-A1 BENZAMIDINE DERIVATIVE Ajinomoto Co., Inc. (JP) 2001-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107290-A1 Benzamidine derivative SERPINE1, SERPINC1, TFPI GPR119 3822/4885F10 21/4885F2 6/4885
US-20010056123-A1 Anticoagulant or an agent for treating or preventing thrombi or emboli SERPINC1, SERPINE1, F2 GPR119 4473/4885F10 16/4885F2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.